[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-365261-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-365261-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","machine-learning-based-prognostic-modelling-of-nk-cells-in-paad-for-immunotherapy-guidance","Machine learning-based prognostic modelling of NK cells in PAAD for immunotherapy guidance","","Pancreatic cancer’s high incidence and mortality rates are driven by ineffective treatments, with immunotherapy showing poor clinical performance. The study attributes this to an insufficiently characterized immune microenvironment, focusing on NK cells as potential key regulators. Using NK differentially expressed genes from the PAAD_GSE162708 single-cell dataset and validating with TCGA-PAAD and ICGC-PACA-AU cohorts, the work builds a prognostic model. Risk scores outperform traditional grading and TNM staging, align with enrichment of neuroactive ligand-receptor interaction and MAPK pathways, and support immunotherapy response prediction, enabling molecular immunotyping and personalized decision-making.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/machine-learning-based-prognostic-modelling-of-nk-cells-in-paad-for-immunotherapy-guidance/365261/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/machine-learning-based-prognostic-modelling-of-nk-cells-in-paad-for-immunotherapy-guidance/365261.png","ImageObject",300,407,{"name":42,"@type":43},"Mia  ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is immunotherapy performance limited in pancreatic adenocarcinoma (PAAD)?","Question",{"text":63,"@type":64},"Immunotherapy’s poor performance is linked to an unclear immune microenvironment, where NK cells may have a distinctive role in regulating the tumor context.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the prognostic model for PAAD constructed and validated?",{"text":68,"@type":64},"The model used NK differentially expressed genes from the PAAD_GSE162708 single-cell dataset and was validated with TCGA-PAAD and ICGC-PACA-AU datasets, along with clinical and pathological analyses.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the functional enrichment analysis suggest about NK cells in PAAD?",{"text":72,"@type":64},"Enrichment highlighted neuroactive ligand-receptor interaction and MAPK signaling pathways, indicating NK cells may contribute to PAAD progression. High-risk groups showed fewer overall NK cells but more activated NK cells, potentially supporting adverse inflammatory responses.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},365261,1790912911,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687207024478,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Analysis  \nMachine learning‑based prognostic modelling of NK cells in PAAD for immunotherapy guidance  \nLi Li1 · Zu‑Tao Wu1 · Wen‑Hong Duan1 · Jiang Liu1 · Yin‑Rong Zhu1  \nReceived: 18 January 2025 / Accepted: 28 March 2025  \n© The Author(s) 2025 OPEN  \nAbstract  \nPancreatic cancer’s high incidence and mortality rates are underscored by ineffective treatments, particularly immunotherapy’s poor performance. This could stem from an unclear immune microenvironment, where NK cells may play a unique role. Analyzing the NK cell-differentially expressed genes (NKDEGs) from the PAAD_GSE162708 singlecell dataset and utilizing the TCGA-PAAD and ICGC-PACA-AU datasets, we identified 11 NKDEGs linked to pancreatic adenocarcinoma (PAAD) prognosis and developed a prognostic model. This model’s risk scores significantly outperformed traditional grading and TNM staging systems, validated through clinical and pathological analyses. Functional enrichment analysis pointed to the Neuroactive ligand-receptor interaction and MAPK signaling pathways, suggesting NK cells’distinctive role in PAAD. High-risk groups showed decreased overall NK cells but increased activated NK cells, which may mediate adverse inflammatory responses. NK cells exhibit synergistic interactions with plasma cells and macrophages and negative regulation by monocytes and naive B cells. Our model accurately predicts immunotherapy responses, indicating potential for targeted drugs to enhance treatment. Additionally, we introduced an NKDEGs-based immunotyping approach for personalized medicine and clinical decision-making in PAAD. This study emphasizes NK cells’ potential in PAAD treatment, offering precise patient stratification and therapeutic targets for immunotherapy.  \nKeywords Machine learning · Immunotherapy · NK cell · Pancreatic cancer · Prognostic model · Molecular subtype  \nAbbreviation  \nPAAD Pancreatic cancer  \n1 Introduction  \nPancreatic cancer (PAAD) is the third leading cause of cancer-related deaths, with pancreatic ductal adenocarcinoma (PDAC) being the predominant pathological type [1] . Due to its rising incidence and relatively stable mortality rate, PAAD is projected to become the second leading cause of cancer-related deaths by 2030 [2] . While surgery and adjuvant chemotherapy can achieve long-term survival, they are only applicable to a small subset of patients with resectable disease [3]. Over the past decade, combined chemotherapy regimens have provided significant options  \nSupplementary Information The online version contains supplementary material available at [https://doi.org/10.1007/s12672-025-](https://doi.org/10.1007/s12672-025-)[ ](https://doi.org/10.1007/s12672-025-)[02266-z](02266-z.)[.](02266-z.)  \n* Yin-Rong Zhu, [15331405346@163.com](15331405346@163.com); Li Li, [15198996931@163.com](15198996931@163.com); Zu-Tao Wu, [wzt199008042021@163.com](wzt199008042021@163.com); Wen-Hong Duan, [15198932382@163.com](15198932382@163.com); Jiang Liu, [lj20241075@163.com |](lj20241075@163.com |1The)[1](lj20241075@163.com |1The)[The](lj20241075@163.com |1The) People’S Hospital of Wenshan Prefecture, Kunming University of Science and Technology, No. 228, Kaihua East Road, Wenshan 663000, Yunnan, China.  \nDiscover Oncology  \n(2025) 16:577  \n| [https://doi.org/10.1007/s12672-025-02266-z](https://doi.org/10.1007/s12672-025-02266-z)  \nfor patients with advanced and metastatic disease, allowing newly diagnosed patients to experience short-term partial remission or disease stabilization. However, nearly all patients eventually relapse, and second-line treatment options are limited [4]. Consequently, the five-year overall survival rate for PAAD patients in the United States is only 9%[5], underscoring the urgent need for alternative treatment strategies. Recent advances in the genomic and immune profiling of PAAD have spurred the development of targeted therapies, but these are currently limited to a small fraction of PAAD patients [6]. Therefore, there is an urgent ","cbCaisphHSg93jL1","https://ap.wps.com/l/cbCaisphHSg93jL1","pdf",9115727,17,"English","# Abstract\n# Introduction\n## Background and clinical need\n## Tumor microenvironment and NK cell relevance","[{\"question\":\"Why is immunotherapy performance limited in pancreatic adenocarcinoma (PAAD)?\",\"answer\":\"Immunotherapy’s poor performance is linked to an unclear immune microenvironment, where NK cells may have a distinctive role in regulating the tumor context.\"},{\"question\":\"How was the prognostic model for PAAD constructed and validated?\",\"answer\":\"The model used NK differentially expressed genes from the PAAD_GSE162708 single-cell dataset and was validated with TCGA-PAAD and ICGC-PACA-AU datasets, along with clinical and pathological analyses.\"},{\"question\":\"What did the functional enrichment analysis suggest about NK cells in PAAD?\",\"answer\":\"Enrichment highlighted neuroactive ligand-receptor interaction and MAPK signaling pathways, indicating NK cells may contribute to PAAD progression. High-risk groups showed fewer overall NK cells but more activated NK cells, potentially supporting adverse inflammatory responses.\"}]","Machine learning-based prognostic modelling of NK cells in PAAD for immunotherapy guidance | PDF",1790160499,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/967be54eb8d172abe9c9bcdb2d7b3282.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ebaceb7453bc2d95c1b725d052eb7c50.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c3c1ddde1594169e8b7376dd30a9f65.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d3291fd9c0cda58671e309cf4cb917e.webp",980,1301]